Neurogene Inc (NAS:NGNE)

$ 25.43 -0.37 (-1.43%) Market Cap: 377.76 Mil Enterprise Value: 253.30 Mil PE Ratio: 0 PB Ratio: 2.41 GF Score: 20/100

Neoleukin Therapeutics Inc Definitive Merger Agreement Conference Call Transcript
Jul 18, 2023
Q2 2022 Neoleukin Therapeutics Inc Earnings Call Transcript
Aug 09, 2022

Earnings
Neoleukin Therapeutics Inc at Bank of America Healthcare Conference Transcript
May 11, 2022
Neoleukin Therapeutics Inc at Canaccord Genuity Horizons in Oncology Conference (Virtual) Transcript
Apr 14, 2022
Q4 2021 Neoleukin Therapeutics Inc Earnings Call Transcript
Mar 01, 2022

Earnings
Neoleukin Therapeutics Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript
Feb 10, 2022
Neoleukin Therapeutics Inc Annual Shareholders Meeting Transcript
May 13, 2021
Neoleukin Therapeutics Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript
May 12, 2021
Q4 2020 Neoleukin Therapeutics Inc Earnings Call Transcript
Mar 25, 2021

Earnings
Neoleukin Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 14, 2021
Q2 2020 Neoleukin Therapeutics Inc Earnings Call Transcript
Aug 12, 2020

Earnings
Neoleukin Therapeutics, Inc. - Special Call Transcript
Jun 23, 2020
Neoleukin Therapeutics Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
May 14, 2020
Neoleukin Therapeutics Inc Annual Shareholders Meeting Transcript
May 05, 2020
Q4 2019 Neoleukin Therapeutics Inc Earnings Call Transcript
Mar 12, 2020

Earnings
Aquinox Pharmaceuticals and Neoleukin Therapeutics Announce Merger Agreement Call Transcript
Aug 06, 2019

Neoleukin Therapeutics Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript

May 12, 2021 / 02:15PM GMT

Transcript 10-Q8-K

Gregory Allen Harrison

BofA Securities, Research Division - Research Analyst

Hi, everyone. Welcome to the second day of the virtual Vegas Bank of America Healthcare Conference. I'm Greg Harrison, one of the biotech analysts here at BofA. And it's my pleasure to welcome Jonathan Drachman, CEO of Neoleukin.

So Jonathan, if you'd like to make any opening remarks, please go ahead, and then we can jump into Q&A.

Jonathan G. Drachman

Neoleukin Therapeutics, Inc. - CEO, President & Director

Thanks, Greg. I'd like to thank you and the organizers in meeting for inviting us to participate. It's a pleasure to be here to talk about the progress that we're making at Neoleukin Therapeutics. We did -- we do have some slides that are uploaded that the viewers will be able to refer to. And I'll just start by saying on Slide 2, we have our forward-looking statement with the risks and forward and I would refer people to the periodic filings with the SEC, which are also available on our website for further information on risk factors.

I'll just maybe

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.